Genesis' breast cancer marker gains patent protection in Australia

By Angela McDaniels

Seattle, Feb. 2 - Genesis Bioventures Inc. said that Mammastatin, the breast cancer marker exclusively licensed to its wholly owned subsidiary Biomedical Diagnostics LLC, has been granted additional patent protection through a Deed of Letters Patent issued to the University of Michigan by the Australian Patent Office.

Biomedical is developing the Mammastatin technology for use in its Mammastatin Serum Assay, a breast cancer risk assessment tool.

The assay was initially developed at the University of Michigan Cancer Center and is licensed to Genesis Bioventures for scientific and commercial development as a blood test to assess women's health.

In scientific correlation studies, women who tested high with the Mammastatin Serum Assay had a lower risk of breast cancer than women who tested low, the company said.

"This is one piece of the domestic and international intellectual property protection strategy we have implemented with the University of Michigan," president Jim Arthurs said in a company news release.

"The issuance of this patent is very important as we gain further regulatory approval and market presence for the Mammastatin technology internationally. This newest patent grant expands our worldwide patent protection for Mammastatin Serum Assay."

Genesis Bioventures is a biomedical development corporation based in New York that develops and markets novel diagnostics and therapeutics in oncology and neurodegenerative diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.